Rare and emerging Candida species

Current Fungal Infection Reports

Volumn 3, Issue 3, 2009, Pages 152-159

  Johnson, Elizabeth M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ANTIMICROBIAL THERAPY; CANDIDA; CANDIDA ALBICANS; CANDIDA BLANKII; CANDIDA BRACARENSIS; CANDIDA CATENULATA; CANDIDA CHIROPTERORUM; CANDIDA CIFERRI; CANDIDA DUBLINIENSIS; CANDIDA EREMOPHILA; CANDIDA FABIANII; CANDIDA FAMATA; CANDIDA FERMENTATI; CANDIDA FREYSCHUSSII; CANDIDA GLABRATA; CANDIDA HAEMULONII; CANDIDA INCONSPICUA; CANDIDA INTERMEDIA; CANDIDA KRUSEI; CANDIDA LAMBICA; CANDIDA MAGNOLIAE; CANDIDA MEMBRANAEFACIENS; CANDIDA METAPSILOSIS; CANDIDA NIVARIENSIS; CANDIDA NORVEGENSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PALMIOLEOPHILA; CANDIDA PARAPSILOSIS; CANDIDA PARARUGOSA; CANDIDA PINTOLOPESII; CANDIDA PSEUDOHAEMULONII; CANDIDA PSEUDORUGOSA; CANDIDA PULCHERRIMA; CANDIDA RUGOSA; CANDIDA THERMOPHILA; CANDIDA TROPICALIS; CANDIDA VALIDA; CANDIDA VISWANATHII; CANDIDA ZEYLANOIDES; CANDIDEMIA; CANDIDIASIS; CLAVISPORA LUSITANIAE; CROSS RESISTANCE; DRUG FATALITY; FUNGAL STRAIN; FUNGEMIA; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION SENSITIVITY; KLUYVEROMYCES MARXIANUS; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; NONHUMAN; OPPORTUNISTIC INFECTION; PICHIA ANOMALA; PICHIA JADINII; POLYMERASE CHAIN REACTION; PREVALENCE; REVIEW; SPECIES DIFFERENTIATION; SPECIES DIVERSITY; SYSTEMIC MYCOSIS; TAXONOMY; YARROWIA LIPOLYTICA; YEAST;

EID: 77950501911     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-009-0020-z     Document Type: Review

References (55)

1. Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20:133-163. This article contains a huge amount of epidemiologic and susceptibility data and offers good insight into current trends.
2. Odds FC: Candida and Candidosis, edn 2. London: Baillière Tindall; 1988.
3. Kibbler CC, Ainscough S, Barnes RA, et al.: Management and outcome of blood stream infections due to Candida species in England and Wales. J Hosp Infect 2003, 54:18-24. (Pubitemid 38002021)
4. Tortorano AM, Peman J, Bernhardt H, et al.: Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23:317-322. (Pubitemid 38669942)
5. Barnett JA, Payne RW, Yarrow D: Yeasts: Characteristics and Identification, edn 3. Cambridge: Cambridge University Press; 2000.
6. Hoog GS, Guarro J, Gené J, et al.: Atlas of Clinical Fungi, edn 2. Utrecht, The Netherlands: Centraalbureau voor Schimmelcultures; 2000.
7. Chen YC, Eisner JD, Kattar MM, et al.: Identification of medically important yeasts using PCR-based detection of DNA sequence polymorphisms in the internal transcribed spacer region 2 of the rRNA genes. J Clin Microbiol 2000, 38:2302-2310. (Pubitemid 30414355)
8. Linton CJ, Borman AM, Cheung, G, et al.: Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years of experience at the United Kingdom Mycology Reference Laboratory. J Clin Microbiol 2007, 45:1152-1158. This article compares molecular versus phenotypic identification for a large number of yeast species, including rare and emerging pathogens.
9. Borman AM, Linton CJ, Oliver D, et al.: Pyrosequencing of 20 nucleotides of the Internal Transcribed Spacer 2 discriminates Candida parapsilosis, Candida metapsilosis and Candida orthopsilosis. J Clin Microbiol 2009, 0:JCM00240-09v1 This article describes a straightforward molecular identification technique with good potential for differentiating closely related species.
10. Nilsson RH, Ryberg M, Kristiansson E, et al.: Taxonomic reliability of DNA sequences in public databases: a fungal perspective. Plos ONE 2006, 1:e59. This is an important article for understanding the limitations of molecular identification.
11. Desnos-Ollivier M, Ragon M, Robert V, et al.: Debaryomyces hansenii (Candida famata), a rare human fungal pathogen often misidentified as Pichia guilliermondii (Candida guilliermondii). J Clin Microbiol 2008, 46:3237-3242. This is an important article for understanding the limitations of phenotypic identification methods.
12. Sullivan DJ, Westerneng TJ, Haynes KA, et al.: Candida dubliniensis sp. Nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 1995, 141:1507-1521.
13. Tavanti A, Davidson AD, Gow NAR, et al.: Candida orthopsilosis and Candida metapsilosis spp. Nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005, 43:284-292. (Pubitemid 40096313)
14. Lan L, Xu J: Multiple gene genealogical analyses suggest divergence and recent clonal dispersal in the opportunistic human pathogen Candida guilliermondii. Microbiology 2006, 152:1539-1549.
15. Odds FC, Van Nuffel L, Dams G: Prevalence of Candida dubliniensis isolates in yeast stock collection. J Clin Microbiol 1998, 35:2869-2873. (Pubitemid 28429406)
16. Odds FC, Hanson MF, Davidson AD, et al.: One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 2007, 56:1066-1075. (Pubitemid 47262669)
17. Sullivan DJ, Moran GP, Colemann DC: Candida dubliniensis: Ten years on. FEMS Microbiol Letters 2005, 253:9-17. (Pubitemid 41605389)
18. Donnelly SM, Sullivan DJ, Shanley DB, et al.: Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences. Microbiology 1999, 145:1871-1882. (Pubitemid 29396917)
19. Mähnss B, Stehr F, Schafer W, et al.: Comparison of standard phenotypic assays with a PCR method to discriminate Candida albicans and C. dubliniensis. Mycoses 2005, 48:55-61. (Pubitemid 40255403)
20. Moran GP, Sullivan DJ, Herman MC, et al.: Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother 1997, 41:617-623. (Pubitemid 27098414)
21. Pfaller MA, Diekema DJ: Minireview: rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004, 42:4419-4431. (Pubitemid 39362350)
22. Gomez-Lopez A, Alatruey-Izquierdo A, Rodriguez D, et al.: Prevalence and susceptibility profile of Candida metapsiolosi and Candida orthopsilosis: results from population-based surveillance of Candidaemia in Spain. Antimicrob Agents Chemother 2008, 52:1506-1509. (Pubitemid 351522020)
23. Lockhart SR, Messer SA, Pfaller MA, et al.: Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol 2008, 46:2659-2664. This is the largest study to date on the relative prevalence of these three closely related species.
24. Gacser A, Schafer W, Nosanchuk JS, et al.: Virulence of Candida parapsiolsis, Candida orthopsilosis and Candida metapsilosis in reconstituted human tissue models. Fungal Genet Biol 2007, 44:1336-1341. (Pubitemid 350046346)
25. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al.: Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003, 47:3149-3154. (Pubitemid 37229571)
26. Pfaller MA, Diekema DJ, Gibbs DL, et al.: Geographical and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008, 46:842-849.
27. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al.: Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretative breakpoints. J Clin Microbiol 2008, 46:2620-2629. This is an important study on breakpoint setting for the echinocandin group of antifungal agents.
28. Mora-Duarte J, Betts R, Rotstein C, et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347:2020-2029. (Pubitemid 35461658)
29. Reboli AC, Rotstein C, Pappas PG, et al.: Anidulafungin versus fluconazole for invasive candidiasis. N Eng J Med 2007, 356:2472-2482. (Pubitemid 46919773)
30. Garcia-Effron G, Katiyar SK, Park S, et al.: A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008, 52:2305-2312. (Pubitemid 351915657)
31. Alcoba-Flôrez J, Méndez-Álvarez S, Cano J, et al.: Phenotypic and molecular characterisation of Candida navariensis sp. nov., a possible new opportunistic fungus. J Clin Microbiol 2005a, 43:4107-4111. (Pubitemid 41129706)
32. Correia A, Sampaio P, James S, et al.: Candida bracarensis sp. Nov., a novel anamorphic yeast species phenotypically similar to Candida glabrata. Int J Syst Evol Micrbiol 2006, 56:313-317. This is the first description of C. bracarensis.
33. Wahyuningsih R, SahBandar IN, Theelen, B, et al.: Candida nivariensis isolated from an Indonesian human immunode-ficiency virus-infected patient suffering from oropharyngeal candidiasis. J Clin Microbiol 2008, 46:388-391.
34. Borman AM, Petch R, Linton CJ, et al.: Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J Clin Microbiol 2008, 46:933-938. (Pubitemid 351379982)
35. Fujita S, Senda Y, Okusi T, et al.: Catheter-related fungaemia due to fluconazole-resistant Candida nivariensis. J Clin Microbiol 2007, 45:3459-3461. (Pubitemid 47585689)
36. Bishop JA, Chase N, Magill SS, et al.: Candida bracarensis detected among isolates of Candida glabrata by peptide nucleic acid fluorescence in situ hybridization: susceptibility data and documentation of presumed infection. J Clin Microbiol 2008, 46:443-446. (Pubitemid 351231284)
37. Lockhart SR, Messer SA, Gherna M, et al.: Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature. J Clin Microbiol 2009, 47:1216-1217. This is the largest epidemiologic study of these three closely related species.
38. Rodero L, Davel G, Soria M, et al.: Multicenter study of bloodstream infections due to yeasts in Argentina [in Spanish]. Revista Argentina de Microbiología 2005, 37:189-195. (Pubitemid 43189505)
39. Dick JD, Rosengard BR, Merz WG, et al.: Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii. Ann Intern Med 1985, 102:67-68. (Pubitemid 15187659)
40. Girmenia C, Pizzarelli G, Cristini F, et al.: Candida guilliermondii fungaemia in patients with hematologic malignancies. J Clin Microbiol 2006, 44:2458-2464. (Pubitemid 44092411)
41. Pfaller MA, Messer SA, Coffman S: In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob Agents Chemother 1997, 41:763-766. (Pubitemid 27150527)
42. Tietz HJ, Czaika V, Sterry W: Case report: osteomyelitis caused by highly resistant Candida guilliermondii. Mycoses 1999, 42:577-580.
43. Barchiesi F, Spreghini E, Tomassetti S, et al.: Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother 2006, 50:2719-2727. (Pubitemid 44198693)
44. Pfaller MA, Messer SA, Bolmstrom A: Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diag Microbiol Infect Dis 1998, 32:223-227. (Pubitemid 29017743)
45. Lockhart SR, Messer SA, Pfaller MA, et al.: Identification and susceptibility profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates. J Clin Microbiol 2009, 47:242-244. This is the largest epidemiologic study of a new cryptic species.
46. Davey KG, Holmes AD, Johnson EM, et al.: Comparative evaluation of FUNGITEST and broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans. J Clin Microbiol 1998, 36:926-930. (Pubitemid 28146270)
47. Espinell-Ingroff A: In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998, 36:198-202.
48. Pfaller MA, Diekema DJ, Colombo AL, et al.: Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program. J Clin Microbiol 2006, 44:3578-3582. This article presents a good overview and large amount of data on this emerging pathogen.
49. Dube MP, Heseltine PNR, Rinaldi MG, et al.: Fungaemia and colonization with nystatin-resistant Candida rugosa in a burn unit. Clin Infect Dis 1994, 18:77-82. (Pubitemid 24025919)
50. Colombo AL, Melo ASA, Rosas RFC, et al.: Outbreak of Candida rugosa candidaemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagn Microbiol Infect Dis 2003, 46:253-257. (Pubitemid 37025761)
51. Li J, Xu YC, Bai FY: Candida pseudorugosa sp. Nov., a novel yeast species from sputum. J Clin Microbiol 2006, 44:4486-4490. (Pubitemid 44937083)
52. Giammanco GM, Melilli D, Pizzo G: Candida pararugosa isolation from the oral cavity of an Italian denture wearer. Res Microbiol 2004, 155:571-574. (Pubitemid 39094209)
53. Nakagawa Y, Robert V, Kawazaki J, et al.: Recurrent isolation of an uncommon yeast, Candida pararugosa, from a sarcoma patient. Med Mycol 2004, 42:267-271. (Pubitemid 38996886)
54. Alter SJ, Farley J: Development of Hansenula anomala infection in a child receiving fluconazole therapy. Pediatr Infect Dis J 1994, 13:158-159. (Pubitemid 24059173)
55. Ribeiro da Matta VL, de Souza Carvalho Melhem M, Colombo AL, et al.: Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungaemia. Antimicrob Agents Chemother 2007, 51:1573-1576. (Pubitemid 46586857)